IDEAYA Biosciences, Inc. · NASDAQ:IDYA

IDEAYA Biosciences — Investor Day (November 2026)

47 slides from IDEAYA Biosciences's investor day presentation, Nov 16, 2026

  1. Slide 1: IDEAYA London R&D Day

    November 16, 2026 IDEAYA London R&D Day Introduction by Yujiro S. Hata, Chairman and CEO, IDEAYA Biosciences

  2. Slide 2: Welcome and Today’s Speakers

    Welcome and Today’s Speakers Inaugural London R&D Day Event Frank McCormick, Ph.D. Yujiro S. Hata Michael White, Ph.D. Theo Ross, M.D., Ph.D. UCSF Helen Diller Cancer Center IDEAYA, Chairman and CEO IDEAYA, President R&D IDEAYA, CDO 2

  3. Slide 3: Agenda

    IDEAYA London R&D Day Agenda • Welcome and introduction (10 mins): Yujiro  IDEAYA’s approach to target tumor heterogeneity and adaptive plasticity in PDAC, NSCLC, and CRC  Our strategy to build industry leading pipeline to address MTAP/CDKN2A- and RAS-driven cancers • 35 Years of RAS Progress, inc

  4. Slide 4: Clinical Combination Strategy Addressing Tumor Heterogeneity and Adaptive Plasticity

    IDEAYA’s Clinical Combination Strategy in PDAC, NSCLC, and CRC is Focused on Addressing The Key Challenges of Tumor Heterogeneity and Adaptive Plasticity • Tumor Heterogeneity  Genetic mutations. Multiple genetic drivers, including oncogenes and tumor suppressor loss  PDAC: KRAS, CDKN2A, MTAP, TP5

  5. Slide 5: Building a Broad First-in-Class & Best-in-Class Precision Oncology Pipeline

    IDEAYA is Building a Broad First-in-Class & Best-in-Class Precision Oncology Pipeline Targeting MTAP, CDKN2A, and KRAS Genetic Alterations in PDAC, NSCLC, and CRC IDEAYA AI/ML-enabled drug discovery engine, including HARMONYTM MTAP/CDKN2A KRAS/Oncogene PDAC, NSCLC NSCLC PDAC, NSCLC CRC, NSCLC PDAC,

  6. Slide 6: Tumor Heterogeneity: Co-Targeting Driver Oncogenes and Tumor Suppressor Loss Genes

    Tumor Heterogeneity: Co-Targeting of Driver Oncogenes and Tumor Suppressor Loss Genes New Potential Treatment Paradigm for Enabling Rational Combinations in PDAC Tumor Driver Suppressor Loss Oncogene IDE892/PRMT5 MTAP-KRAS Pan-RAS Clinical PoC In-Place MTAP KRAS IDE397/MAT2A ~40% PDAC KRAS G12D IDEA

  7. Slide 7: Rational Combinations to Address MTAP/CDKN2A/KRAS in PDAC, NSCLC, and CRC

    IDEAYA London R&D Day Focus Rational Combinations to Address MTAP/CDKN2A/KRAS in PDAC, NSCLC, and CRC • IDEAYA combination strategies target to address tumor heterogeneity and adaptive plasticity  IDE892 (PRMT5) + pan-RAS: MTAP/KRAS (FPI targeted Q4 2026)  IDE892 (PRMT5) + KRAS G12D: MTAP/KRAS G12

  8. Slide 8: 35 Years of RAS Progress - Recent Breakthroughs and Future Challenges

    November 16, 2026 35 Years of RAS Progress - Recent Breakthroughs and Future Challenges Dr. Frank McCormick, Professor of the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

  9. Slide 9: RAS: The Clinical Need

    RAS: The Clinical Need KRAS is the primary driver in pancreatic cancer and lung adenocarcinoma 9

  10. Slide 10: Challenges of Targeting RAS

    Challenges of Targeting RAS The “squishy tennis ball” Out IN 10

  11. Slide 11: RAS Proteins Regulate MAP Kinase to Drive CDK Dependent Cell Proliferation

    RAS Proteins Regulate MAP Kinase to Drive CDK Dependent Cell Proliferation KRAS Intrinsic GTP Raf inhibitors paradoxically activate Raf kinase hydrolysis RAS SOS GAPs RAF MEK ERK MEK and ERK inhibitors are too toxic Cyclin D1 CDK4/6 S-Phase, CDK2 activation 11

  12. Slide 12: Oncogenic RAS Proteins Activate PI 3’ Kinase

    Oncogenic RAS Proteins Activate PI 3’ Kinase KRAS G12D, KRAS G12V RRAS, RRAS2 Intrinsic GTP hydrolysis RAS SOS RAS GAPs RAF PIK3CA MEK PTEN PIP3 ERK Cyclin D1 AKT CDK4/6 mTOR S-Phase Enhances PRMT5 potency 12

  13. Slide 13: 2013: First Compounds That Bind Directly to KRAS

    2013: First Compounds That Bind Directly to KRAS • Revealed a druggable pocket in KRAS, the Switch Two pocket (Shokat pocket) • 28 KRAS G12C drugs in the clinic. Most hit the OFF-state 13

  14. Slide 14: 2021: First Non-Covalent KRAS G12D Binder

    2021: First Non-Covalent KRAS G12D Binder, with Picomolar Affinity ~95 KRAS targeted therapies in the clinic 27 KRAS G12D binders in the clinic. Most bind the OFF state 14

  15. Slide 15: Resistance to OFF-State KRAS Binders

    Resistance to OFF-State KRAS Binders • Increased upstream signaling from EGF, other RTKs, increase GTP binding • Increased expression of KRAS overcomes the OFF-state trap Receptor Tyrosine Kinases 15

  16. Slide 16: Tri-complex RAS-GTP (ON) Selective Inhibitors

    Tri-complex RAS-GTP (ON) Selective Inhibitors • Role of GTP hydrolysis? • Effect of inhibiting wild type RAS in tumor stroma, immune cells, etc.? Side effects can be severe • Resistance through loss of cyclophilin A 16

  17. Slide 17: Mechanisms of RAS Resistance

    Mechanisms of RAS Resistance Resistance based on unique mechanism • OFF-state inhibitors: hyper-activation of upstream RTK signaling, increased expression of KRAS • Tri-complex (ON) inhibitors: Loss/mutation of cyclophilin A, increased expression of KRAS General mechanisms for targeted therapies • M

  18. Slide 18: Future Directions in RAS

    Future Directions in RAS • Combinations, such as PRMT5 and pan-RAS for targeting driver co-alterations with RAS • New focus on colorectal cancer  Most KRAS inhibitors focused on lung (G12C) and pancreatic cancer (G12D and G12V)  Adagrasib + cetuximab approved, then approval was withdrawn • Inciden

  19. Slide 19: IDEAYA’s Approach to MTAP/CDKN2A and KRAS-driven Cancers

    November 16, 2026 IDEAYA’s Approach to MTAP/CDKN2A and KRAS-driven Cancers Dr. Michael White, President R&D, IDEAYA Biosciences Dr. Theo Ross, Chief Development Officer, IDEAYA Biosciences

  20. Slide 20: IDE892, a Potential Best-in-Class PRMT5 Inhibitor Designed for Superior Combinability

    IDE892, a Potential Best-in-Class PRMT5 Inhibitor Designed for Superior Combinability PRMT5 Priority Opportunities in PDAC with Roche RG6505 (pan-Ras) and Genentech GDC-7035 (KRASG12D) PRMT5 and KRAS biology are MTAP deletion alters cellular Opportunity for maximal pathway intertwined response to pa

  21. Slide 21: IDE892 Potent Target Engagement with Wide MTAP Selectivity Window

    Augmented Tumor-Selective Activity via MTA-Cooperativity and SAM-Negative Cooperativity IDE892 Delivers Potent Target Engagement Together with a Wide MTAP Selectivity Window In-vitro target binding (+/- MTA) In-vitro cofactor selectivity (MTA vs. SAM) In-vivo activity selectivity (MTAPwt vs. MTAPdel

  22. Slide 22: Robust Preclinical Combination Benefit with Pan-Ras Inhibitor Across PDAC Models

    Robust Preclinical Combination Benefit with Pan-Ras Inhibitor Across PDAC Models IDE892 Delivers Strong Regressions in Recalcitrant Models at Clinically Relevant Exposures KP-4 (KRAS G12D) SU.86.86 (KRAS G12D) CAPAN-1 (KRAS G12V) PANC-1 (KRAS G12D) 2000 1250 1500 Vehicle 1500 Mean Tumor Volume (mm3)

  23. Slide 23: IDE892 Phase 1/2 Clinical Development Overview

    IDE892 Phase 1/2 Clinical Development Overview Potential Monotherapy and Combination Opportunities in MTAP-Deletion Solid Tumors Preliminary Strategy Target Clinical Development Plan • Pursue IDE892 monotherapy IDE892 and combinations in MTAP Dose Escalation Expansion Cohort: NSCLC PDAC and NSCLC Mo

  24. Slide 24: IDE892 Phase 1 Demonstrates Potential Best-in-Class PRMT5 Safety Profile

    IDE892 Phase 1 Study Demonstrates Potential Best-in-Class PRMT5 Safety Profile Predominantly Grade 1 to 2 TRAEs. No Observed DLTs and MTD Not Reached Most common TRAEs, all grades (% of 31) By dose level (DL) Patients on 31 monotherapy 5 dose cohorts 0 20 40 60 80 100 Dose N Any TRAE (Patient #) Gr

  25. Slide 25: IDE892 Favorable QD Dosing Human PK and Target EC90 Coverage

    IDE892 Demonstrates Favorable QD Dosing Human PK and Achieves Target EC90 Coverage at ≥DL3, and Not Anticipated to Have CNS Exposure Based on Preclinical Evaluation Cellular target EC90 coverage for 24h at DL3 Very limited CNS exposures in dog and rat Steady State PK Profiles Dog toxicity study Low

  26. Slide 26: IDE892 Phase 1 Pharmacodynamic Plasma SDMA Suppression Results

    IDE892 Phase 1 Study Pharmacodynamic Plasma SDMA Suppression Results At IDE892 DL3, ~60% Median Plasma SDMA Suppression Observed: Comparable to the Maximal Median % SDMA Suppression Reported for Navlimetostat (BMS-986504) at the 600mg QD RP3D1 Exposure and Pharmacodynamic Correlation IDE892 Phase 1

  27. Slide 27: IDE892 Confirmed PR in 3L Cholangiocarcinoma MTAP Patient

    DL3 Cohort: IDE892 Confirmed PR by RECIST 1.1 in 3L Cholangiocarcinoma MTAP Patient Partial Response Observed at Week 6 (-31%) which Deepened and Confirmed at Week 12 (-60%) 3L cholangiocarcinoma: DL3 Cohort: 3L Cholangiocarcinoma MTAP patient Baseline Week 12 • 65-year-old male with MTAP, CDKN2A/B,

  28. Slide 28: IDE892 Optimized for Favorable DDI Profile to Enable Clinical Combos

    IDE892 was Optimized for Favorable DDI Profile to Enable Clinical Combos That Has Been Substantiated in Phase 1 Combo Study with IDE397, a Largely CYP3A4-Metabolized Agent IDE892 Reversible CYP Inhibition Phase 1 Combo with IDE892 + IDE397 Observed favorable EC50s for the 7 Does Not Demonstrate CYP3

  29. Slide 29: AMG 193 + IDE397 Combo Confirmed PR in 4L Cholangio MTAP Patient

    AMG 193 + IDE397 Combo Confirmed PR by RECIST 1.1 in 4L Cholangio MTAP Patient Durable Partial Responses (PR) Observed at Sub-Therapeutic AMG 193 (PRMT5) Monotherapy Dose 4L cholangiocarcinoma: Baseline Week 18 • 35 years old female with MTAP, CDKN2A/B, BAP1, EPHA7, NF1 • Prior therapies: Durva + Ge

  30. Slide 30: IDE892 Phase 1 Clinical Program Summary and Upcoming Milestones

    IDE892 Phase 1 Clinical Program Summary and Upcoming Milestones • IDE892 dose expansion evaluation (DL3, DL4, and DL5) to determine RP3D • IDE892 + IDE397 dose escalation ongoing and targeting expansion H1 2027 in MTAP NSCLC • IDE892 + pan-RAS combo FPI targeted in Q4 2026 • ID892 + KRAS G12D combo

  31. Slide 31: Accelerating Discovery with Predictive Physics Calculations Augmented by AI/ML

    Accelerating Discovery with Predictive Physics Calculations Augmented by AI/ML AI/ML IDEAYA AI/ML-Assisted FEP Platform Fast-Tracks Time to DC Across Discovery Programs FEP compute bottleneck solved with advanced Improved throughput enables improved model and parameter optimization compound selectio

  32. Slide 32: Unleashing the Potential of Generative Design

    Unleashing the Potential of Generative Design Physics-First Approach: FEP Quantum Calculation Paired with AI/ML Delivers Robust AI-Design Options Structure based design Distributed selection of designs for Enrich real binders with physics- enumeration FEP calculations trained ML-based method • FIC h

  33. Slide 33: Enabling Scalable Next-Generation Target Prosecution

    Enabling Scalable Next-Generation Target Prosecution AI/ML-Optimized Virtual Screening (VS) Protocols Built on Rigorous Physics-Based Computation Current VS protocols Large virtual library Internal advances for problematic when applied (enumerated or generative) to FIC targets application of VS to F

  34. Slide 34: IDE574 is a Dual KAT6/7 Inhibitor with Broad Opportunity in Breast, NSCLC, and CRC

    IDE574 is a Dual KAT6/7 Inhibitor with Broad Opportunity in Breast, NSCLC, and CRC KAT6/7 IDE574: potent dual KAT6/7 inhibitor to overcome paralog bypass Durable anti-tumor activity achieved through driver pathway control Histone acetyltransferases KAT6A/B and KAT7 collaboratively Superior suppressi

  35. Slide 35: Drug Synergy Screens Nominate IDE574 and RAS Combination in CRC

    Empircal Drug Synergy Screens Nominate IDE574 and RAS Combination in CRC IDE574 Intercepts Adaptive Cell-State Transitions Otherwise Supporting RAS-resistance Drug synergy screen highlights RAS interaction Perturbation of adaptive cell states underpins IDE574/daraxonrasib synergy CRC models: drug SW

  36. Slide 36: IDE574 + RAS Delivers Durable Regressions in CRC

    IDE574 + RAS Delivers Durable Regressions in CRC Through Control of WNT/MYC Activity Top differential pathway modulation with combination therapy (day 3) Robust regressions observed with daraxonrasib combination indicates amplified suppression of WNT and PI3K signaling SW620 (CRC, KRAS G12V, APCmut)

  37. Slide 37: Strong IDE574 and Daraxonrasib Combo Synergy in KRAS NSCLC

    Strong IDE574 and Daraxonrasib Combo Synergy Also Broadly Observed in KRAS NSCLC Reciprocal Reinforcement of Lineage-Dependent Drug-Responsive Cell-States Drug synergy screen highlights RAS interaction Expression profiles indicate combinatorial reinforcement of RASi-responsive states NCIH2122 (KRAS

  38. Slide 38: Robust Combination Benefit in NSCLC Associated with Suppression of Drug Adaptation

    Robust Combination Benefit in NSCLC Associated with Suppression of Drug Adaptation Top differential pathway modulation with combination therapy Apparent in vivo synergy observed indicates amplified suppression of MAPK and NRF2 signaling 2500 NCIH2122 (LUAD, KRAS G12C, KEAP1 mut) MAPK6/MAPK4 RAS sign

  39. Slide 39: IDE574 Phase 1/2 Clinical Development Overview

    IDE574 Phase 1/2 Clinical Development Overview Potential Monotherapy and Combination Opportunities in Breast, and KRAS CRC and NSCLC Preliminary Strategy Target Clinical Development Plan • Target indications of Breast, CRC, and NSCLC. IDE574 Combinations with SERD Dose Escalation Expansion Cohort: B

  40. Slide 40: IDE574 Phase 1 Demonstrates a Manageable Safety Profile

    IDE574 Phase 1 Study Demonstrates a Manageable Safety Profile TRAEs Mostly Grade 1 and 2 and MTD Not Yet Reached. No G4/5 TRAEs and Dose Escalation Ongoing Most common TRAEs, all grades (% of 32) By dose level Patients on 32 monotherapy 5 dose cohorts 0 20 40 60 80 100 Dose N Any TRAE Gr 3 Dysgeusia

  41. Slide 41: IDE574 Rapid PR in 5L ER+ BC Patient

    DL4 Cohort: IDE574 Rapid PR (-40%) by RECIST 1.1 in 5L ER+ BC Patient & Treatment Ongoing Preliminary KAT6 and KAT7 Ph1 Pharmacodynamic Data Demonstrates Strong Target Engagement First-in-World reported Partial Response by a KAT6/7 Dual Inhibitor DL4 Cohort: 5L ER+ Breast Cancer Patient* KAT6 & KAT7

  42. Slide 42: IDE101, a Potential FIC Dual CDK Inhibitor to Unlock CDKN2A-Deficiency

    IDE101, a Potential FIC Dual CDK Inhibitor to Unlock CDKN2A-Deficiency CDKN2A 9p21.3 Deletions ~15% of All Cancers; CDKN2A Deficiency >70% PDAC; KRAS Activation >90% PDAC Majority of PDAC is CDKN2A deficient CDKN2A deficiency unleashes G1 cyclin-dependent IDE101 offers the opportunity to intercept t

  43. Slide 43: IDE101 CDK-family Selectivity Profile Optimized for Tumor-Selective Suppression

    IDE101 CDK-family Selectivity Profile Optimized for Maximal Tumor-Selective Suppression of Oncogene-Driven Cell Proliferation IDE101 can extinguish oncogene-driven S-phase G1 CDK/Cyclin mediated E2F Superior E2F inhibition across 1250 ESR1-driven model Mean Tumor Volume (mm3) ± S.E.M. activation ind

  44. Slide 44: Mechanistic Synergy with pan-RAS Inhibitor Offers Potential Impact in PDAC

    Mechanistic Synergy with pan-RAS inhibitor Offers Potential For Clinical Impact in PDAC Synergy observed with pan-RASi across majority of KRAS-mutant PDAC models Combination delivers superior durability MIA PaCa-2 PDAC cell lines (N=10) (KRAS G12C, CDKN2A/MTAP loss) 40000 MIA PaCa-2 IDE101 DMSO 3000

  45. Slide 45: Durable Complete Responses in PDAC in Combination with KRAS Inhibitors

    Durable Complete Responses Observed in PDAC in Combination with KRAS Inhibitors at CRD Functional Synergy Observed in Combination Relative to Monotherapy Responses KP4, KRAS G12D, CDKN2A/MTAP loss, TP53 WT, MiaPaCa2, KRAS G12C, CDKN2A/MTAP loss, Collaborative suppression of tumor pRb MYC amp, HGF-ME

  46. Slide 46: IDE101 Can Rescue Anti-Tumor Activity Post Daraxonrasib Relapse

    IDE101 Can Rescue Anti-Tumor Activity Post Daraxonrasib Relapse in PDAC and NSCLC Targeting RAS/CDKN2A Co-Alterations in PDAC. Aassessments in NSCLC Emerging Capan-1, KRAS G12V, CDKN2A/MTAP loss, NCI-H2122, KRAS G12C; CDKN2A LoF, Derived daraxonrasib-resistant MIA PaCa-2 retains TP53mut,(PDAC) TP53,

  47. Slide 47: IDEAYA London R&D Day Summary and Analyst Q&A

    IDEAYA London R&D Day Summary and Analyst Q&A Multiple 2027 Target Catalysts and Clinical Data Readouts in MTAP/CDKN2A and KRAS IDEAYA AI/ML-enabled drug discovery engine, including HARMONYTM MTAP/CDKN2A KRAS/Oncogene PDAC, NSCLC NSCLC PDAC, NSCLC CRC, NSCLC PDAC, CRC, NSCLC PRMT5 MAT2A CDKN2A KAT6/

IDEAYA Biosciences — Investor Day (November 2026) on 6ix